Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
08 Novembro 2021 - 8:00AM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women and for men, today announced the
appointment of Nancy Valente, M.D. as an independent member of the
company’s Board of Directors. Dr. Valente is a renowned expert in
hematology and oncology drug development with over 20 years of
experience leading global development programs at Genentech/Roche
and other leading pharmaceutical companies involving novel
first-in-class molecules. In addition to her Board appointment, Dr.
Valente will chair the Board’s Nominating and Corporate Governance
Committee and be a member of the Audit Committee.
“We are excited to welcome Dr. Valente to our Board,” said David
Marek, Chief Executive Officer of Myovant Sciences, Inc. “Her deep
experience in drug development and impressive track record leading
teams through successful regulatory approvals will be invaluable as
Myovant continues to build its pipeline through lifecycle
management and potential business development to enable long-term
sustainable growth.”
In her most recent role, Dr. Valente was Senior Vice
President and Co-lead for Global Product Development,
Oncology, Hematology Development Therapeutic Area at Roche. In this
role, she was responsible for setting the strategy for the
department, clinical development, collaboration activities, and
budget management. She played a critical role in the
development of new therapies for patients with serious illnesses,
including the approvals of GAZYVA®, VENCLEXTA®, POLIVY®, and
HEMLIBRA®. Previously, she held various positions with
increasing responsibilities at Genentech and then at Roche after
Genentech was acquired by Roche, including Vice President for
Global Product Development for Oncology, Hematology Franchise and
Senior Group Medical Director, Leader for Hematology Development.
Prior to Genentech, she served in senior-level positions at Anosys,
Inc. and Coulter Pharmaceutical, Inc. Dr. Valente has held academic
positions at the University of California, San Francisco (UCSF)
where her most recent role was Assistant Adjunct Clinical Professor
of Medicine specializing in breast cancer. Dr. Valente
received her medical degree from the University of Missouri and
completed her internal medicine training at Oregon Health &
Science University, followed by fellowships in Hematology at
Stanford University and Oncology at UCSF.
“I am honored to serve on the Board of Directors of Myovant
Sciences,” said Dr. Valente. “Myovant has had tremendous success
conducting global clinical trials that resulted in three regulatory
approvals and product launches within the past 12 months. I look
forward to supporting Myovant as it embarks on its exciting next
phase of growth in expanding its pipeline and portfolio for
patients who need new and effective treatment options.”
About Myovant SciencesMyovant
Sciences aspires to redefine care for women and for men
through purpose-driven science, empowering medicines, and
transformative advocacy. Founded in 2016, Myovant
Sciences has two FDA-approved products.
ORGOVYX® (relugolix) was approved by the U.S. Food and
Drug Administration in 2020 as the first and only oral
gonadotropin-releasing hormone (GnRH) receptor antagonist for the
treatment of adult patients with advanced prostate cancer, and
relugolix is also under regulatory review in Europe for
men with advanced prostate cancer. Relugolix combination tablet
(relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5
mg) was approved in 2021 in the U.S. as
MYFEMBREE® as the first once-daily treatment for the
management of heavy menstrual bleeding associated with uterine
fibroids in premenopausal women, and by the European
Commission and the Medicines and Healthcare products
Regulatory Agency as RYEQO® for the treatment of moderate to
severe symptoms of uterine fibroids in adult women of reproductive
age. Myovant Sciences filed a supplemental New Drug
Application for MYFEMBREE for the management of moderate to severe
pain associated with endometriosis, which was accepted for review
by the FDA in September 2021. MYFEMBREE is also being assessed
for the prevention of pregnancy. Myovant Sciences is also
developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist,
which has completed a Phase 2a study for female infertility as part
of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly
owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is Myovant
Sciences’ majority shareholder. For more information, please visit
our website at www.myovant.com. Follow @Myovant on
Twitter and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. In this press
release, forward-looking statements include, but are not limited
to, all statements reflecting Myovant Sciences’ expectations,
including but not limited to: statements regarding Myovant’s
building of its pipeline through lifecycle management and potential
business development to enable long-term sustainable growth and
Myovant's expansion of its pipeline and portfolio for patients who
need new and effective treatment options.
Myovant Sciences’ forward-looking statements are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties, assumptions, and other factors
known and unknown that could cause actual results and the timing of
certain events to differ materially from future results expressed
or implied by the forward-looking statements, including unforeseen
circumstances or other disruptions to normal business operations
arising from or related to the COVID-19 pandemic. Myovant
Sciences cannot assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or
occur and actual results could differ materially from those
expressed or implied by these forward-looking statements. Factors
that could materially affect Myovant Sciences’ operations and
future prospects or which could cause actual results to differ
materially from expectations include, but are not limited to, the
risks and uncertainties listed in Myovant Sciences’ filings with
the United States Securities and Exchange
Commission (SEC), including under the heading “Risk Factors”
in Myovant Sciences’ Quarterly Report on Form 10-Q filed
on October 26, 2021, as such risk factors may be amended,
supplemented, or superseded from time to time. These risks are not
exhaustive. New risk factors emerge from time to time and it is not
possible for Myovant Sciences’ management to predict all risk
factors, nor can Myovant Sciences assess the impact of
all factors on its business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
You should not place undue reliance on the forward-looking
statements in this press release, which speak only as of the date
hereof, and, except as required by law, Myovant
Sciences undertakes no obligation to update these
forward-looking statements to reflect events or circumstances after
the date of such statements.
Investor Contact:Ryan CroweVice President,
Investor Relations+1 (650) 781-9106investors@myovant.com
Media Contact:Albert LiaoDirector, Corporate
Communications+1 (650) 410-3055media@myovant.com
Myovant Sciences (NYSE:MYOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Myovant Sciences (NYSE:MYOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024